3 Beaten-Down Biotech Stocks -- Are They Bargains Now?
Investors' attraction to biotechnology reached a fever pitch at the beginning of 2021. Since then, things have gone from bad to worse. The benchmark SPDR S&P Biotech ETF (NYSEMKT: XBI) recently started to recover, but it's still down more than 33% from a peak it reached this February.
These three biotech stocks have fallen hard recently along with the rest of their industry. Is this a chance to pick up one or more former high flyers at a bargain-basement discount? Read on to find out.
Image source: Getty Images.
Source Fool.com
